Armistice Capital LLC Buys New Stake in Kazia Therapeutics Limited (NASDAQ:KZIA)

Armistice Capital LLC bought a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 2,475,555 shares of the company’s stock, valued at approximately $1,088,000. Armistice Capital LLC owned about 15.15% of Kazia Therapeutics at the end of the most recent reporting period.

Kazia Therapeutics Trading Up 4.1 %

Kazia Therapeutics stock traded up $0.01 during midday trading on Wednesday, hitting $0.26. 27,572 shares of the company’s stock were exchanged, compared to its average volume of 584,367. Kazia Therapeutics Limited has a 12-month low of $0.19 and a 12-month high of $1.34. The firm’s 50 day simple moving average is $0.32 and its 200 day simple moving average is $0.35.

Kazia Therapeutics Profile

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.